source
- PepGen soars on promising early data for muscular dystrophy drugWhile from a small study, the findings suggest PepGen’s therapy compares favorably to other RNA-based medicines in testing at Novartis and Dyne Therapeutics.BioPharma Dive · 4d ago↗ source
- Oura to buy AI care startup Counsel Health for $625MWearable ringmaker Oura is buying AI primary care startup Counsel Health. Oura is paying $625 million in cash for Counsel, which offers medical AI services as well as virtual visits with doctors. T…Endpoints · 4d ago↗ source
- Delix raises $100M to advance at-home psychedelic without hallucinogenic effectsThe series C raise, co-led by Johnson & Johnson’s venture capital arm, will help Delix Therapeutics push its novel psychedelic asset into mid-stage development for major depressive disorder.